Fast Growing Mid-Tier Pharmaceutical Company Signs Agreement with eResearchTechnology for Cardiac Safety Monitoring and Informat
23 December 2003 - 3:33AM
PR Newswire (US)
Fast Growing Mid-Tier Pharmaceutical Company Signs Agreement with
eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services Award Totals Approximately $1.2 Million and
Includes Digital Collection, Interpretation, and Distribution of
Cardiac Safety Data PHILADELPHIA, Dec. 22 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), , a leading provider of
centralized electrocardiographic (ECG) collection and
interpretation services, announced today that it has received an
agreement for approximately $1.2 million in cardiac safety
monitoring and services from a fast growing mid-tier pharmaceutical
for one of its drug candidates in late phase development. The
agreement covers a Phase III study that will be conducted at 60
research sites in the U.S. eRT will provide comprehensive site
support and 60 units of 12-lead ECG recording equipment, which is
designed to facilitate the collection of cardiac safety data that
are subsequently provided to eRT for analysis. eRT will manage
collection, measurement, interpretation, review, and distribution
of cardiac safety data through its EXPeRT workflow enabled data
handling technology, the first solution in production that was
designed explicitly to meet emerging international regulatory
guidance and technical standards. In addition, the agreement
includes a subscription to eRT's Digital ECG Community, which
delivers timely cardiac safety data feedback at the trial, center,
dosing group, and patient level, along with related metrics, such
as trial enrollment, as well as the ability to organize and publish
a variety of study-specific information and the ability to link
data points in reports direct to digital ECG waveforms. "This
agreement represents the fourth significant study for this compound
that has been awarded to eRT in the past two months," said Scott
Grisanti, senior vice president of business development and chief
marketing officer at eRT. "Scientific and technical consistency of
cardiac safety evaluation services across an entire drug
development program is growing in importance. This trend encourages
the sponsor to evaluate an ECG core laboratory's capacity and
throughput capabilities in addition to these other important
areas." Based in Philadelphia, PA, eResearchTechnology, Inc.
(http://www.ert.com/) is a provider of technology and services to
the pharmaceutical, biotechnology and medical device industries on
a global basis. The company is a market leader in providing
centralized core-diagnostic electrocardiographic (ECG) technology
and services to evaluate cardiac safety in clinical development.
The company is also a leader in providing technology and services
to streamline the clinical trials process by enabling its customers
to automate the collection, analysis, and distribution of clinical
data in all phases of clinical development. Statements included in
this release may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and
the company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and
duration of projects, and internal issues in the sponsoring client.
As a result, actual results may differ materially from any
financial outlooks stated herein. Further information on potential
factors that could affect the company's financial results can be
found in the company's Reports on Forms 10-K and 10-Q filed with
the Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci,
eResearchTechnology, Inc., +1-908-203-6473, or Matt Hayden, Hayden
Communications, +1-760-487-1137, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles